Central retinal and posterior ciliary artery occlusion after intralesional injection of sclerosant to glabellar subcutaneous hemangioma.
The aim of this study is to describe vision loss caused by central retinal artery and posterior ciliary artery occlusion as a consequence of sclerotherapy with a polidocanol injection to a glabellar hemangioma. An 18-year-old man underwent direct injection with a 23-gauge needle of 1 mL of a polidocanol-carbon dioxide emulsion into the glabellar subcutaneous hemangioma under ultrasound visualization of the needle tip by radiologists. He developed lid swelling the next day, and 3 days later at referral, the visual acuity in the left eye was no light perception. Funduscopy revealed central retinal artery occlusion and fluorescein angiography disclosed no perfusion at all in the left fundus, indicating concurrent posterior ciliary artery occlusion. The patient also showed mydriasis, blepharoptosis, and total external ophthalmoplegia on the left side. Magnetic resonance imaging demonstrated the swollen medial rectus muscle. In a month, blepharoptosis and ophthalmoplegia resolved but the visual acuity remained no light perception. Sclerosing therapy for facial hemangioma may develop a severe complication such as permanent visual loss.
Matsuo
Toshihiko
T
Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama City, 700-8558, Japan. matsuot@cc.okayama-u.ac.jp
Fujiwara
Hiroyasu
H
Gobara
Hideo
H
Mimura
Hidefumi
H
Kanazawa
Susumu
S
D000293:Adolescent; D019842:Ciliary Arteries / Q000473:pathology*; D005451:Fluorescein Angiography; D018324:Hemangioma, Capillary / Q000628:therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009669:Nose Neoplasms / Q000628:therapy*; D019721:Ophthalmoscopes; D000077423:Polidocanol; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D015356:Retinal Artery Occlusion / Q000139:chemically induced* / Q000175:diagnosis; D012597:Sclerosing Solutions / Q000008:administration & dosage / Q000009:adverse effects*; D015911:Sclerotherapy / Q000009:adverse effects*; D014792:Visual Acuity
D012597:Sclerosing Solutions; D000077423:Polidocanol; D011092:Polyethylene Glycols